Business context and reporting period
Prestige Brands Holdings, Inc. (the issuer named in the filing; the request metadata identifies Prestige Consumer Healthcare Inc.) markets and distributes over-the-counter healthcare and household-cleaning products. This Form 10-Q covers the three months ended June 30, 2015, the first quarter of fiscal 2016, with comparison to the three months ended June 30, 2014. Results include Insight Pharmaceuticals from its September 2014 acquisition; the prior-year quarter does not.
Financial performance
| Metric | Q1 FY2016 | Q1 FY2015 | Change |
|---|---|---|---|
| Total revenue | $192.1 million | $145.7 million | +31.9% |
| Gross profit / margin | $112.2 million / 58.4% | $81.9 million / 56.2% | +37.1%; +2.2 pts |
| Operating income / margin | $62.5 million / 32.5% | $42.8 million / 29.4% | +46.0% |
| Net income | $26.2 million | $16.7 million | +56.4% |
| Diluted EPS | $0.49 | $0.32 | +$0.17 |
| Operating cash flow | $43.5 million | $29.7 million | +$13.8 million |
Advertising and promotion expense rose to $26.4 million from $19.1 million, while depreciation and amortization increased to $5.7 million from $3.0 million, primarily reflecting acquired Insight intangibles. Interest expense rose to $21.9 million from $14.7 million as average debt increased; the average borrowing cost declined to 5.5% from 6.0%. The company recorded a $0.5 million loss on extinguishment of debt. Effective tax rate was 34.8%, versus 40.6%.
Cash, liquidity and debt
Cash was $21.6 million at June 30, compared with $21.3 million at March 31. Investing activities used $0.4 million, versus $78.5 million in the prior-year quarter, which included the $78.0 million Hydralyte acquisition. Financing activities used $42.9 million, including $25.0 million of term-loan repayments, $20.0 million net revolver repayments and $4.2 million of debt-issuance costs. Capital expenditures were $0.8 million.
Outstanding principal debt was $1,548.6 million at quarter-end, down from $1,593.6 million at March 31; net debt after cash was approximately $1,527.0 million. The debt mix included $852.5 million of term loans, $46.1 million drawn on the ABL revolver and $650.0 million of senior notes. ABL borrowing capacity was $63.0 million. The term loan was refinanced into Term B-3 loans in May, with a 2.75% LIBOR margin and 0.75% LIBOR floor; the ABL maturity was extended to June 2020. The company reported compliance with debt covenants at June 30.
Material changes versus the prior comparable period
- Revenue growth was led by North American OTC Healthcare, up 40.9%; Insight contributed $42.5 million of segment revenue. Women’s Health revenue rose sharply with the acquired portfolio, while Dermatologicals and Eye & Ear Care also benefited from Insight.
- International OTC Healthcare revenue increased 3.5%; Household Cleaning revenue increased 3.4%. The company attributed consolidated growth primarily to Insight and higher sales from certain core brands.
- Gross margin improved, mainly due to the acquired brands’ margins and favorable North American product mix. Contribution margin was $85.8 million, or 44.7% of revenue, versus $62.8 million, or 43.1%.
- Operating cash flow improved, while the prior-year period’s large acquisition outflow did not recur. The current period’s financing cash outflow reflected debt repayments and refinancing-related costs.
Outlook, commentary and risks
- Management gave no consolidated revenue, earnings or cash-flow guidance in the supplied filing text. It expected an approximately 35.4% effective tax rate for the remaining fiscal 2016 quarters, excluding acquisitions and discrete items.
- Management expects certain product costs to rise during the remainder of fiscal 2016; inability to offset increases with pricing could pressure gross margins.
- Supply constraints affected women’s-health and analgesics products. The company was using or arranging alternative manufacturers and suppliers, but warned unresolved issues could limit product availability and harm sales and results.
- PediaCare and certain other brands had recent revenue declines. Management said it continued impairment monitoring; sustained deterioration or adverse valuation assumptions could lead to a non-cash impairment charge. No impairment was recorded in the quarter.
- Concentration risks include Walmart, which represented 19.9% of gross revenue and 21.8% of receivables, and the five leading brands, which represented 43.9% of revenue. The business also depends on third-party manufacturers and a principal U.S. distribution center.
- The filing identifies two products subject to ongoing recalls and early-stage discussions with regulators regarding a product-registration matter. It warns of potential regulatory enforcement, additional costs or product-sale restrictions.
- CEO Matthew Mannelly retired effective June 1, 2015; then-CFO Ron Lombardi succeeded him as CEO. Accelerated vesting associated with the retirement resulted in approximately $0.8 million of additional compensation expense.
- Interest-rate risk is material: $898.6 million of debt was variable-rate. The filing estimates a 1 percentage-point increase would adversely affect quarterly pretax earnings and cash flows by approximately $2.3 million, holding other factors constant.
- Goodwill and intangible assets totaled $2.42 billion, most of total assets, making valuation sensitive to sales, margins, competition, consumer preferences and discount-rate assumptions. The filing also notes substantially all cash balances were uninsured.
Most important facts for investors to verify
- Confirm the issuer identity and reporting period: the filing is for Prestige Brands Holdings, Inc., quarter ended June 30, 2015.
- Separate acquisition-driven growth from organic performance; Insight accounted for $42.5 million of North American segment revenue growth, and certain legacy brands continued to decline.
- Track supply recovery for women’s-health and analgesics products, the replacement active-ingredient supplier, and any effect on sales or customer availability.
- Monitor debt reduction, variable-rate exposure, available revolver capacity and covenant headroom given the company’s substantial leverage and interest burden.
- Review impairment indicators for PediaCare and other brands, as well as recall and regulatory developments, including the product-registration discussions.
- Assess customer and brand concentration, and whether higher input costs can be offset without weakening margins.